Acinetobacter baumannii has emerged as a highly troublesome pathogen for many institutions globally. As a consequence of its immense ability to acquire or upregulate antibiotic drug resistance determinants, it has justifiably been propelled to the forefront of scientific attention. Apart from its predilection for the seriously ill within intensive care units, A. baumannii has more recently caused a range of infectious syndromes in military personnel injured in the Iraq and Afghanistan conflicts. This review details the significant advances that have been made in our understanding of this remarkable organism over the last 10 years, including current taxonomy and species identification, issues with susceptibility testing, mechanisms of antibiotic resistance, global epidemiology, clinical impact of infection, host-pathogen interactions, and infection control and therapeutic considerations.

Acinetobacter baumannii: Emergence of a Successful Pathogen

beta-Lactamases are the commonest single cause of bacterial resistance to beta-lactam antibiotics. Numerous chromosomal and plasmid-mediated types are known and may be classified by their sequences or phenotypic properties. The ability of a beta-lactamase to cause resistance varies with its activity, quantity, and cellular location and, for gram-negative organisms, the permeability of the producer strain. beta-Lactamases sometimes cause obvious resistance to substrate drugs in routine tests; often, however, these enzymes reduce susceptibility without causing resistance at current, pharmacologically chosen breakpoints. This review considers the ability of the prevalent beta-lactamases to cause resistance to widely used beta-lactams, whether resistance is accurately reflected in routine tests, and the extent to which the antibiogram for an organism can be used to predict the type of beta-lactamase that it produces.

https://courses.washington.edu/pharm522/Week9/0139.pdf

beta-Lactamases in laboratory and clinical resistance.

Summary: AmpC β-lactamases are clinically important cephalosporinases encoded on the chromosomes of many of the Enterobacteriaceae and a few other organisms, where they mediate resistance to cephalothin, cefazolin, cefoxitin, most penicillins, and β-lactamase inhibitor-β-lactam combinations. In many bacteria, AmpC enzymes are inducible and can be expressed at high levels by mutation. Overexpression confers resistance to broad-spectrum cephalosporins including cefotaxime, ceftazidime, and ceftriaxone and is a problem especially in infections due to Enterobacter aerogenes and Enterobacter cloacae, where an isolate initially susceptible to these agents may become resistant upon therapy. Transmissible plasmids have acquired genes for AmpC enzymes, which consequently can now appear in bacteria lacking or poorly expressing a chromosomal blaAmpC gene, such as Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. Resistance due to plasmid-mediated AmpC enzymes is less common than extended-spectrum β-lactamase production in most parts of the world but may be both harder to detect and broader in spectrum. AmpC enzymes encoded by both chromosomal and plasmid genes are also evolving to hydrolyze broad-spectrum cephalosporins more efficiently. Techniques to identify AmpC β-lactamase-producing isolates are available but are still evolving and are not yet optimized for the clinical laboratory, which probably now underestimates this resistance mechanism. Carbapenems can usually be used to treat infections due to AmpC-producing bacteria, but carbapenem resistance can arise in some organisms by mutations that reduce influx (outer membrane porin loss) or enhance efflux (efflux pump activation).

AmpC β-Lactamases

INTRODUCTION 149 TAXONOMY 149 Historical Features 149 Current Taxonomic Status 149 Delineation of Species 149 Species of Clinical Importance 150 LABORATORY IDENTIFICATION 150 Isolation from Clinical Specimens 150 Morphological, Cultural, and Metabolic Characteristics 151 Species Identification 151 NOSOCOMIAL INFECTIONS CAUSED BY ACINETOBACTER SPP. 152 Overview 152 Respiratory Infection 152 Bacteremia 153 Meningitis 153 Urinary Tract Infection 154 Other Miscellaneous Infections 154 PATHOGENESIS OF ACINETOBACTER INFECTIONS 154 Predisposing Factors 154 Virulence of Acinetobacter spp. 154 EPIDEMIOLOGY 155 Human Carriage 155 Persistence in the Hospital Environment 155 TYPING SYSTEMS 156 Biotyping 156 Antibiograms 156 Serotyping 156 Phage Typing 157 Bacteriocin Typing 157 Protein Profiles 157 Multilocus Enzyme Electrophoretic Typing 157 Plasmid Profiles 157 Analysis by Pulsed-Field Gel Electrophoresis 157 Ribotyping 157 PCR-Based Methods 158 CLINICAL ANTIBIOTIC RESISTANCE 158 BIOCHEMICAL AND GENETIC MECHANISMS OF ANTIBIOTIC RESISTANCE 158 Genetics of Resistance 158 b-Lactams 159 Aminoglycosides 159 Quinolones 160 Other Antibiotics 160 THERAPY OF ACINETOBACTER INFECTIONS 160 CONCLUSIONS 160 ACKNOWLEDGMENTS 161 REFERENCES 161

/pdf/acinetobacter-spp-as-nosocomial-pathogens-microbiological-430u90opiv.pdf

Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Since the 1970s, the spread of multidrug-resistant (MDR) Acinetobacter strains among critically ill, hospitalized patients, and subsequent epidemics, have become an increasing cause of concern. Reports of community-acquired Acinetobacter infections have also increased over the past decade. A recent manifestation of MDR Acinetobacter that has attracted public attention is its association with infections in severely injured soldiers. Here, we present an overview of the current knowledge of the genus Acinetobacter, with the emphasis on the clinically most important species, Acinetobacter baumannii.

/pdf/an-increasing-threat-in-hospitals-multidrug-resistant-4mki9sim2r.pdf

An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii.

Acinetobacter baumannii is an opportunistic nosocomial pathogen and one of the six most important multidrug-resistant microorganisms in hospitals worldwide. This human pathogen is responsible for a vast array of infections, of which ventilator-associated pneumonia and bloodstream infections are the most common, and mortality rates can reach 35%. Community-acquired infections have also been reported, but few strains have been recovered from environmental sources and infection reservoirs external to the hospital have not been identified. The majority of A. baumannii infections are caused by two main population clones with worldwide distribution. Infection outbreaks are often associated with multidrug resistance, including the recent emergence of strains resistant to all available antibiotics. Nevertheless, A. baumannii virulence traits and pathogenic potential have mostly remained elusive. The recent expansion of A. baumannii sequenced genomes has permitted the development of large-array phylogenomic and phenotypic analyses, which can offer valuable insights into the evolution and adaptation of A. baumannii as a human pathogen. This review summarises these recent advances, with particular focus on A. baumannii evolutionary and genomic aspects, and proposes new avenues of research.

/pdf/acinetobacter-baumannii-evolution-of-a-global-pathogen-18x6esffhq.pdf

Acinetobacter baumannii: evolution of a global pathogen.

These evidence-based guidelines have been produced after a literature review of the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). We have considered the detection of MRSA in screening samples and the detection of reduced susceptibility to glycopeptides in S. aureus. Recommendations are given for the identification of S. aureus and for suitable methods of susceptibility testing and screening for MRSA and for S. aureus with reduced susceptibility to glycopeptides. These guidelines indicate what tests should be used but not when the tests are applicable, as aspects of this are dealt with in guidelines on control of MRSA. There are currently several developments in screening media and molecular methods. It is likely that some of our recommendations will require modification as the new methods become available.

/pdf/guidelines-for-the-laboratory-diagnosis-and-susceptibility-4w8lx3nfeh.pdf

Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA)

Acinetobacter: an old friend, but a new enemy

The genus Acinetobacter comprises a complex and heterogeneous group of bacteria, many of which are capable of causing a range of opportunistic, often catheter-related, infections in humans. However, Acinetobacter baumannii, as well as its close relatives belonging to genomic species 3 ("Acinetobacter pittii") and 13TU ("Acinetobacter nosocomialis"), are important nosocomial pathogens, often associated with epidemic outbreaks of infection, that are only rarely found outside of a clinical setting. These organisms are frequently pandrug-resistant and are capable of causing substantial morbidity and mortality in patients with severe underlying disease, both in the hospital and in the community. Several epidemic clonal lineages of A. baumannii have disseminated worldwide and seem to have a selective advantage over non-epidemic strains. The reasons for the success of these epidemic lineages remain to be elucidated, but could be related to the potential of these organisms to achieve very dynamic reorganization and rapid evolution of their genome, including the acquisition and expression of additional antibiotic resistance determinants, under fluctuating environmental and selective conditions.

https://iubmb.onlinelibrary.wiley.com/doi/pdf/10.1002/iub.534

Kevin J. Towner

Papers

Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Acinetobacter baumannii: evolution of a global pathogen.

Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA)

Acinetobacter: an old friend, but a new enemy

Acinetobacter infection--an emerging threat to human health.